PMID- 30766826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 22
IP  - 6
DP  - 2018 Nov-Dec
TI  - Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other 
      Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus.
PG  - 827-836
LID - 10.4103/ijem.IJEM_162_17 [doi]
AB  - Involvement of multiple physiological pathways and complex pathogenesis is 
      responsible for the onset and progression of type 2 diabetes mellitus (T2DM). 
      Since it is difficult to manage multiple pathophysiological defects by 
      monotherapy, a combination therapy with two or more oral antidiabetic agents 
      (OADs) may help achieve euglycemia in T2DM patients. Choice of OADs is difficult 
      with growing armamentarium of antidiabetic therapy. Ideally, drug combination 
      should aim at reversal of known pathogenic abnormalities and demonstrate 
      improvement in the overall metabolic health rather than simply reduce 
      glycosylated hemoglobin (HbA1c) levels. Increased glucose reabsorption, a faulty 
      pathological mechanism, is targeted by a novel class of drugs, namely, the 
      sodium-glucose cotransporter-2 (SGLT2) inhibitors. Combination of SGLT2 
      inhibitors and other OADs complement each other due to their unique mechanism of 
      action. In addition, the glucose-lowering effect of SGLT2 inhibitors remains 
      independent of beta-cell function and insulin sensitivity which reduces the chances 
      of severe hypoglycemia in patients receiving these agents. Clinical studies from 
      the past favor the use of SGLT2 inhibitors in combination with other agents to 
      achieve better HbA1c levels, weight loss, and blood pressure control. In this 
      review, we have made an attempt to explore the recommended guidelines for 
      combination therapy, its advantages as either combination therapy or fixed-dose 
      combinations therapy, and the role of SGLT2 inhibitors as a choice of drug as a 
      combination with other OADs.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana, India.
FAU - Kesavadev, Jothydev
AU  - Kesavadev J
AD  - Department of Diabetes, Jothydev's Diabetes and Research Centre, 
      Thiruvananthapuram, Kerala, India.
FAU - Chadha, Manoj
AU  - Chadha M
AD  - P. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
FAU - Kumar, G Vijaya
AU  - Kumar GV
AD  - Diabetes Medicare Centre, Chennai, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC6330851
OTO - NOTNLM
OT  - Combination therapy
OT  - glucose-lowering effect
OT  - oral antidiabetic drugs
OT  - sodium-glucose cotransporter-2 inhibitors
OT  - type 2 diabetes mellitus
COIS- There are no conflicts of interest.
EDAT- 2019/02/16 06:00
MHDA- 2019/02/16 06:01
PMCR- 2018/11/01
CRDT- 2019/02/16 06:00
PHST- 2019/02/16 06:00 [entrez]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2019/02/16 06:01 [medline]
PHST- 2018/11/01 00:00 [pmc-release]
AID - IJEM-22-827 [pii]
AID - 10.4103/ijem.IJEM_162_17 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):827-836. doi: 
      10.4103/ijem.IJEM_162_17.